Cleveland BioLabs, Inc. reported that Chief Development Officer, Jean Viallet, MD will leave the company to assume an oncology global clinical research leadership role at Bristol-Myers Squibb, effective January 3, 2014.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0007 USD | 0.00% | 0.00% | -99.98% |
2023 | Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs. | CI |
2023 | Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
+40.31% | 54.04B | |
+45.43% | 41.96B | |
-1.63% | 41.92B | |
-7.20% | 28.35B | |
+11.70% | 26.35B | |
-21.55% | 19B | |
+5.96% | 13B | |
+29.12% | 12.28B | |
+25.34% | 12.19B |
- Stock Market
- Equities
- STAB Stock
- STAB Stock
- News Statera Biopharma, Inc.
- Cleveland BioLabs Announces Departure of Jean Viallet, Effective January 3, 2014